Page 59 - NobleCon19revC2_Neat

Citius Pharmaceuticals, Inc.

SELECTED FINANCIAL ITEMS CTXR

(in millions of USD)
CQ4 '22 CQ1 '23 CQ2 '23 CQ3 '23 LTM
Income Statement Key Items
Total Revenue NA NA NA NA 0.00
Gross Profit NA NA NA NA 0.00
Gross Margin NM NM NM NM NM
EBIT (7.55) (7.25) (10.69) (8.67) (34.16)
EBIT Margin NM NM NM NM NM
Net Income to Common Shareholders (7.99) (3.59) (10.53) (8.48) (30.59)
Net Margin NM NM NM NM NM

Balance Sheet Key Items
Total Assets 114.00 111.71 104.24 110.40 110.40
Cash & Short Term Investments 41.71 36.89 29.07 33.28 33.28
% of Assets 37% 33% 28% 30% 30%
Current Assets -Total 44.56 42.32 34.90 41.11 41.11
% of Assets 39% 38% 33% 37% 37%
Total Liabilities 10.57 10.67 12.43 12.10 12.10
% of Assets 9% 10% 12% 11% 11%
Current Liabilities - Total 4.53 4.54 6.21 5.79 5.79
% of Assets 4% 4% 6% 5% 5%
Long Term Debt NA NA NA NA NA
% of Assets NM NM NM NM NM
Total Equity 103.43 101.03 91.81 98.30 98.30
% of Assets 91% 90% 88% 89% 89%

Cash Flow Statement Key Items
Net Cash Flow - Operating Activities (6.33) (4.82) (7.85) (9.58) (28.59)
Net Cash Flow - Investing NA NA NA NA 0.00
Net Cash Flow - Financing NA NA 0.03 13.80 13.83

Source: Capital IQ

PRICE / VOLUME

Source: Channelchek/QuoteMedia

Noble Capital Markets' Nineteenth Annual Small & Microcap Investor Conference